| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1949312 | Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2013 | 19 Pages |
Lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), the most prominent lysoglycerophospholipids, are emerging as a novel class of inflammatory lipids, joining thromboxanes, leukotrienes and prostaglandins with which they share metabolic pathways and regulatory mechanisms. Enzymes that participate in LPC and LPA metabolism, such as the phospholipase A2 superfamily (PLA2) and autotaxin (ATX, ENPP2), play central roles in regulating LPC and LPA levels and consequently their actions. LPC/LPA biosynthetic pathways will be briefly presented and LPC/LPA signaling properties and their possible functions in the regulation of the immune system and chronic inflammation will be reviewed. Furthermore, implications of exacerbated LPC and/or LPA signaling in the context of chronic inflammatory diseases, namely rheumatoid arthritis, multiple sclerosis, pulmonary fibrosis and hepatitis, will be discussed. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.
► LPC and LPA signaling is implicated in chronic inflammatory disorders. ► LPA is a pleiotropic growth factor. ► PLA2 is a drug target in MS. ► ATX is a novel player in chronic inflammatory disorders and an emerging drug target.
